Anastasia Darwitan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anastasia Darwitan has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Anu Maashaa Nedumaran
School of Materials Science & Engineering, Nanyang Technological University, Singapore, 639798, Singapore
2 shared publications- Bertrand Czarny
School of Materials Science and Engineering, Nanyang Technological University, Singapore
2 shared publications - Subramanian S. Venkatraman
Material Science & Engineering, National University of Singapore, Singapore 117546, Singapore
2 shared publications - Yee Shan Wong
School of Materials Science & Engineering, Nanyang Technological University, Singapore 639798, Singapore
2 shared publications Anita Vincent
School of Materials Science & Engineering, Nanyang Technological University, Singapore, 639798, Singapore
1 shared publicationAristo Muktabar
School of Materials Science & Engineering, Nanyang Technological University, Singapore, 639798, Singapore
1 shared publication
Latest Publications
- 16 June 2020
- Published by Wiley in Advanced Healthcare Materials
- Vol. 9 (14) , e2000465
Liposomal Nanotherapy for Treatment of Atherosclerosis
Atherosclerosis is a chronic disease that can lead to life‐threatening events such as myocardial infarction and stroke, is characterized by the build‐up of lipids and immune cells within the arterial wall. It is understood that inflammation is a hallmark of atherosclerosis and can be a target for therapy. In support of this concept, an injectable nanoliposomal formulation encapsulating fluocinolone acetonide (FA), a corticosteroid, is developed that allows for drug delivery to atherosclerotic plaques while reducing the systemic exposure to off‐target tissues. In this study, FA is successfully incorporated into liposomal nanocarriers of around 100 nm in size with loading efficiency of 90% and the formulation exhibits sustained release up to 25 d. The anti‐inflammatory effect and cholesterol efflux capability of FA‐liposomes are demonstrated in vitro. In vivo studies carried out with an apolipoprotein E‐knockout (Apoe−/−) mouse model of atherosclerosis show accumulation of liposomes in atherosclerotic plaques, colocalization with plaque macrophages and anti‐atherogenic effect over 3 weeks of treatment. This FA‐liposomal‐based nanocarrier represents a novel potent nanotherapeutic option for atherosclerosis.
- 16 June 2020
- Published by Wiley in Advanced Healthcare Materials
- Vol. 9 (14) , e2000465
Liposomal Nanotherapy for Treatment of Atherosclerosis
Atherosclerosis is a chronic disease that can lead to life‐threatening events such as myocardial infarction and stroke, is characterized by the build‐up of lipids and immune cells within the arterial wall. It is understood that inflammation is a hallmark of atherosclerosis and can be a target for therapy. In support of this concept, an injectable nanoliposomal formulation encapsulating fluocinolone acetonide (FA), a corticosteroid, is developed that allows for drug delivery to atherosclerotic plaques while reducing the systemic exposure to off‐target tissues. In this study, FA is successfully incorporated into liposomal nanocarriers of around 100 nm in size with loading efficiency of 90% and the formulation exhibits sustained release up to 25 d. The anti‐inflammatory effect and cholesterol efflux capability of FA‐liposomes are demonstrated in vitro. In vivo studies carried out with an apolipoprotein E‐knockout (Apoe−/−) mouse model of atherosclerosis show accumulation of liposomes in atherosclerotic plaques, colocalization with plaque macrophages and anti‐atherogenic effect over 3 weeks of treatment. This FA‐liposomal‐based nanocarrier represents a novel potent nanotherapeutic option for atherosclerosis.
- 15 June 2020
- Published by Taylor & Francis in Expert Opinion on Drug Delivery
- Vol. 17 (8) , 1165-1176
Targeting efficiency of nanoliposomes on atherosclerotic foam cells: polyethylene glycol-to-ligand ratio effects
Nanoparticles that actively target tissues, with ligands attached at the extremity of polyethylene glycol (PEG) spacer, are a promising strategy to enhance target cell specificity and internalizati...
- 15 June 2020
- Published by Taylor & Francis in Expert Opinion on Drug Delivery
- Vol. 17 (8) , 1165-1176
Targeting efficiency of nanoliposomes on atherosclerotic foam cells: polyethylene glycol-to-ligand ratio effects
Nanoparticles that actively target tissues, with ligands attached at the extremity of polyethylene glycol (PEG) spacer, are a promising strategy to enhance target cell specificity and internalizati...